Neuralstem, Inc. (NASDAQ:CUR) Posts Quarterly Earnings Results, Beats Expectations By $9.10 EPS
Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings results on Tuesday. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.49) by $9.10, Bloomberg Earnings reports. Neuralstem had a negative net margin of 191,652.16% and a negative return on equity of 425.79%.
Neuralstem (NASDAQ:CUR) traded down 3.57% during midday trading on Wednesday, reaching $1.08. 429,157 shares of the company’s stock were exchanged. The stock’s market cap is $12.85 million. Neuralstem has a 12 month low of $1.03 and a 12 month high of $6.60. The firm has a 50 day moving average of $4.95 and a 200-day moving average of $4.57.
Separately, ValuEngine lowered shares of Neuralstem from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th.
In other Neuralstem news, CEO Richard J. Daly purchased 7,500 shares of Neuralstem stock in a transaction on Wednesday, May 17th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the chief executive officer now directly owns 23,312 shares of the company’s stock, valued at $93,248. The purchase was disclosed in a filing with the SEC, which is available at this link. 15.43% of the stock is owned by company insiders.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.